Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Subjects With Refractory or Relapsed Acute Myeloid Leukemia

NCT03766126 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT03766126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03766126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Lead sponsor
University of Pennsylvania
Phase
Phase 1
Overall status
Terminated
Start date
December 6, 2018
Completion date
March 5, 2026
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, adult, acute myeloid leukemia, in relapse, acute myeloid leukemia, refractory